Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

PREDICTING MINS WITH FRAILTY AND BIOMARKERS IN GERIATRIC SURGERY

NCT07566013 · tracked via the Priya Life Science Turkey tracker
Sponsor
DİLEK KALAYCI
Phase
Observational
Started
2026-04-01
Last updated
2026-05-04

Condition(s) studied

Geriatric PatientsPostoperative ComplicationsFrailtyMyocardial IschemiaHip Surgeries

Investigational drug(s) / intervention(s)

Preoperative Risk Assessment and Machine Learning Modeling

Preoperative Risk Assessment and Machine Learning Modeling: Standard clinical care for major orthopedic surgery including preoperative assessment of biomarkers (hs-cTnT, NT-proBNP), frailty screening (mFI-5), and clinical data collection for the development of a machine learning-based MINS prediction model.

Study summary

The primary objective of this study is to develop and validate a machine learning model that integrates preoperative clinical data, biomarkers, and modified frailty indices (mFI-5) to accurately predict myocardial injury after non-cardiac surgery (MINS) in geriatric patients ($\\ge$65 years) undergoing major orthopedic surgery and requiring postoperative intensive care. The research aims to compare the predictive performance of advanced algorithms, such as XGBoost and Random Forest, against traditional clinical risk scores like the Revised Cardiac Risk Index (RCRI), while specifically evaluating the impact of frailty on the model's area under the curve (AUC). Furthermore, by identifying the most critical preoperative predictors, this study seeks to establish an objective clinical decision support mechanism to guide clinicians in the early risk stratification of high-risk geriatric patients.

Eligibility

Sex
ALL
Min age
65 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All patients aged 65 years and older. * Patients undergoing major orthopedic surgery (hip fracture repair, total knee/hip arthroplasty, and revision surgeries). * Patients operated on within the designated study period (January 2021 - December 2023). * Patients with complete access to preoperative clinical data (comorbidities, medication use) and baseline laboratory parameters (Hemoglobin, Creatinine, Albumin). * Patients who had at least one postoperative cardiac troponin (hs-cTn) measurement within the first 72 hours after surgery. Exclusion Criteria: * Patients with a documented history of acute myocardial infarction or elevated baseline troponin levels in the preoperative period (to differentiate acute injury from surgical causes). * Patients with end-stage renal disease (ESRD) requiring dialysis (as chronic kidney dysfunction persistently elevates baseline troponin levels). * Patients with missing critical preoperative data or incomplete postoperative troponin follow-up.

Primary outcome measure(s)

  • Incidence of Myocardial Injury after Non-cardiac Surgery (MINS) — 30 days postoperatively
    The area under the receiver operating characteristic curve (AUC-ROC) ,Percentage of participants)

Trial sites (1)

FacilityCityRegionStatus
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Ankara Ankara
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07566013 on ClinicalTrials.gov ↗ ← All trials in Turkey